These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 12535387

  • 21. Malaria vaccine.
    Khurana SK, Talib VH.
    Indian J Pathol Microbiol; 1996 Dec; 39(5):433-41. PubMed ID: 9002371
    [Abstract] [Full Text] [Related]

  • 22. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela.
    Noya O, Gabaldón Berti Y, Alarcón de Noya B, Borges R, Zerpa N, Urbáez JD, Madonna A, Garrido E, Jimenéz MA, Borges RE.
    J Infect Dis; 1994 Aug; 170(2):396-402. PubMed ID: 8035026
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique.
    Campo JJ, Sacarlal J, Aponte JJ, Aide P, Nhabomba AJ, Dobaño C, Alonso PL.
    Vaccine; 2014 Apr 17; 32(19):2209-16. PubMed ID: 24631081
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garçon N, Krzych U, Marchand M.
    N Engl J Med; 1997 Jan 09; 336(2):86-91. PubMed ID: 8988885
    [Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, Owusu R, Shomari M, Leach A, Jongert E, Salim N, Fernandes JF, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Möller T, Apanga S, Mwangoka G, Dubois MC, Madi T, Kwara E, Minja R, Hounkpatin AB, Boahen O, Kayan K, Adjei G, Chandramohan D, Carter T, Vansadia P, Sillman M, Savarese B, Loucq C, Lapierre D, Greenwood B, Cohen J, Kremsner P, Owusu-Agyei S, Tanner M, Lell B.
    Lancet Infect Dis; 2011 Oct 09; 11(10):741-9. PubMed ID: 21782519
    [Abstract] [Full Text] [Related]

  • 32. Clinical and parasitological studies on immunity to Plasmodium falciparum malaria in children.
    Høgh B.
    Scand J Infect Dis Suppl; 1996 Oct 09; 102():1-53. PubMed ID: 9060051
    [Abstract] [Full Text] [Related]

  • 33. Serological responses of Gambian children to immunization with the malaria vaccine SPf66.
    Metzger WG, Haywood M, D'Alessandro U, Drakeley CJ, Weiss H, Bojang K, Targett GA, Greenwood BM.
    Parasite Immunol; 1999 Jul 09; 21(7):335-40. PubMed ID: 10417667
    [Abstract] [Full Text] [Related]

  • 34. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
    Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q, Guinovart C, Espasa M, Corachan S, Lievens M, Navia MM, Dubois MC, Menendez C, Dubovsky F, Cohen J, Thompson R, Ballou WR.
    Lancet; 2005 Dec 10; 366(9502):2012-8. PubMed ID: 16338450
    [Abstract] [Full Text] [Related]

  • 35. Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66.
    Millet P, Campbell GH, Sulzer AJ, Grady KK, Pohl J, Aikawa M, Collins WE.
    Am J Trop Med Hyg; 1993 Mar 10; 48(3):424-31. PubMed ID: 7682382
    [Abstract] [Full Text] [Related]

  • 36. The march toward malaria vaccines.
    Hoffman SL, Vekemans J, Richie TL, Duffy PE.
    Vaccine; 2015 Nov 27; 33 Suppl 4(Suppl 4):D13-23. PubMed ID: 26324116
    [Abstract] [Full Text] [Related]

  • 37. Protective efficacy and safety of radiation-attenuated and chemo-attenuated Plasmodium Falciparum sporozoite vaccines against controlled and natural malaria infection: a systematic review and meta-analysis of randomized controlled trials.
    Abuelazm MT, Elzeftawy MA, Kamal MA, Badr H, Gamal M, Aboulgheit M, Abdelazeem B, Abd-Elsalam S, Abouzid M.
    Infection; 2024 Jun 27; 52(3):707-722. PubMed ID: 38319556
    [Abstract] [Full Text] [Related]

  • 38. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
    Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM, Hill AS.
    PLoS Med; 2004 Nov 27; 1(2):e33. PubMed ID: 15526058
    [Abstract] [Full Text] [Related]

  • 39. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.
    Kashala O, Amador R, Valero MV, Moreno A, Barbosa A, Nickel B, Daubenberger CA, Guzman F, Pluschke G, Patarroyo ME.
    Vaccine; 2002 May 22; 20(17-18):2263-77. PubMed ID: 12009282
    [Abstract] [Full Text] [Related]

  • 40. Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study.
    Ballou WR, Blood J, Chongsuphajaissidhi T, Gordon DM, Heppner DG, Kyle DE, Luxemburger C, Nosten F, Sadoff JC, Singhasivanon P.
    Parasitology; 1995 May 22; 110 Suppl():S25-36. PubMed ID: 7784126
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.